Literature DB >> 29134314

Surgery for Primary Hyperparathyroidism with Normal Non-suppressed Parathyroid Hormone can be Both Challenging and Successful.

Lauren E Orr1, Travis J McKenzie1, Geoffrey B Thompson1, David R Farley1, Robert A Wermers2, Melanie L Lyden3.   

Abstract

BACKGROUND: Criteria for diagnosing primary hyperparathyroidism (PHPT) include hypercalcemia in the presence of parathyroid hormone (PTH) levels that are either elevated (classic PHPT) or normal but non-suppressed. However, there is no standard definition of what constitutes normal non-suppressed levels, and data are lacking regarding the potential for surgical cure in these patients.
METHODS: A retrospective review of patients undergoing parathyroidectomy for sporadic PHPT between 2012 and 2014 was performed. Patients with normal PTH were compared to classic PHPT patients to assess demographics, imaging, operative findings, and outcomes.
RESULTS: In total, 332 patients met study criteria, and 60 (18%) had normal PTH levels. Negative sestamibi scans were seen more often with normal PTH levels (18.3 vs. 4.8%, p < 0.001). Patients with normal PTH were more likely to have ≥2 glands removed (26.7 vs. 14.3%, p = 0.02), and the specimens were more likely to be classified as only mildly hypercellular or normocellular (20 vs. 2.9%, p < 0.001). Average follow-up was 24 months (range 6-55). Cure rate was 88% in the normal PTH group, compared to 96% in classic PHPT (p = 0.02). Among patients with normal PTH, those with PTH ≤ 55 pg/mL had an 83% cure rate, whereas those with PTH 56-65 had a 96% cure rate (p = 0.12).
CONCLUSIONS: Parathyroidectomy can have a high cure rate in the context of normal PTH levels despite an increased likelihood of negative imaging and multigland resection. Operative success is equivalent to classic PHPT when PTH levels are > 55 pg/mL.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29134314     DOI: 10.1007/s00268-017-4323-x

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  19 in total

1.  The necessity and reliability of intraoperative parathyroid hormone (PTH) testing in patients with mild hyperparathyroidism and PTH levels in the normal range.

Authors:  Amal Alhefdhi; Scott N Pinchot; Ruth Davis; Rebecca S Sippel; Herbert Chen
Journal:  World J Surg       Date:  2011-09       Impact factor: 3.352

2.  Primary hyperparathyroidism with normal serum intact parathyroid hormone levels.

Authors:  C Mischis-Troussard; P Goudet; B Verges; P Cougard; C Tavernier; J F Maillefert
Journal:  QJM       Date:  2000-06

3.  The American Association of Endocrine Surgeons Guidelines for Definitive Management of Primary Hyperparathyroidism.

Authors:  Scott M Wilhelm; Tracy S Wang; Daniel T Ruan; James A Lee; Sylvia L Asa; Quan-Yang Duh; Gerard M Doherty; Miguel F Herrera; Janice L Pasieka; Nancy D Perrier; Shonni J Silverberg; Carmen C Solórzano; Cord Sturgeon; Mitchell E Tublin; Robert Udelsman; Sally E Carty
Journal:  JAMA Surg       Date:  2016-10-01       Impact factor: 14.766

4.  Normal PTH levels in primary hyperparathyroidism: still the same disease?

Authors:  Amanda L Amin; Tracy S Wang; Thomas J Wade; Tina W F Yen
Journal:  Ann Surg Oncol       Date:  2011-05-03       Impact factor: 5.344

5.  Normohormonal primary hyperparathyroidism is a distinct form of primary hyperparathyroidism.

Authors:  Megan K Applewhite; Michael G White; Jennifer Tseng; Maryam K Mohammed; Frederic Mercier; Edwin L Kaplan; Peter Angelos; Tamara Vokes; Raymon H Grogan
Journal:  Surgery       Date:  2016-11-17       Impact factor: 3.982

6.  Primary hyperparathyroidism revisited in menopausal women with serum calcium in the upper normal range at population-based screening 8 years ago.

Authors:  Ewa Lundgren; Emil G Hagström; Jonas Lundin; Kajsa Winnerbäck; Johanna Roos; Sverker Ljunghall; Jonas Rastad
Journal:  World J Surg       Date:  2002-06-06       Impact factor: 3.352

Review 7.  Elevated PTH with normal serum calcium level: a structured approach.

Authors:  Rachel K Crowley; Neil J Gittoes
Journal:  Clin Endocrinol (Oxf)       Date:  2016-03-21       Impact factor: 3.478

8.  Calcium infusion suggests a "set-point" abnormality of parathyroid gland function in familial benign hypercalcemia and more complex disturbances in primary hyperparathyroidism.

Authors:  S Khosla; P R Ebeling; A F Firek; M M Burritt; P C Kao; H Heath
Journal:  J Clin Endocrinol Metab       Date:  1993-03       Impact factor: 5.958

9.  Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype.

Authors:  H Lowe; D J McMahon; M R Rubin; J P Bilezikian; S J Silverberg
Journal:  J Clin Endocrinol Metab       Date:  2007-05-29       Impact factor: 5.958

10.  Primary hyperparathyroidism with normal baseline intraoperative parathyroid hormone: A challenging population.

Authors:  Mahsa Javid; Glenda Callender; Courtney Quinn; Tobias Carling; Patricia Donovan; Robert Udelsman
Journal:  Surgery       Date:  2016-10-04       Impact factor: 3.982

View more
  2 in total

1.  Surgical management of MILD hyperparathyroidism.

Authors:  Adèle Lecourt; Gwenaëlle Creff; Paul Coudert; Olivier De Crouy Chanel; Pascal Guggenbuhl; Franck Jegoux
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-07-30       Impact factor: 2.503

Review 2.  Recent advances in the understanding and management of primary hyperparathyroidism.

Authors:  Melanie Goldfarb; Frederick R Singer
Journal:  F1000Res       Date:  2020-02-25
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.